Table 3 Multivariable analysis of risk factors for outcome after second allogeneic stem cell transplantation.

From: Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

Variable

Level

LFS

OS

RI

NRM

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

Period of transplant

2000–2004

1

 

1

 

1

 

1

 

2005–2009

0.62 (0.39–0.99)

0.046

0.61 (0.38–0.98)

0.04

0.52 (0.3–0.91)

0.02

0.95 (0.34–2.7)

0.93

2010–2014

0.5 (0.32–0.79)

0.003

0.48 (0.3–0.76)

0.002

0.41 (0.24–0.72)

0.002

0.73 (0.26–2.05)

0.55

2015–2019

0.53 (0.34–0.83)

0.01

0.47 (0.3–0.74)

<0.001

0.44 (0.25–0.76)

0.003

0.77 (0.27–2.15)

0.61

Type of donor for alloSCT2

MSD

1

 

1

 

1

 

1

 

Haplo

1.13 (0.89–1.44)

0.30

1.34 (1.04–1.73)

0.02

0.93 (0.68–1.28)

0.66

1.88 (1.2–2.97)

0.01

URD

1.13 (0.92–1.38)

0.26

1.32 (1.05–1.66)

0.02

0.89 (0.69–1.14)

0.35

2.14 (1.42–3.23)

<0.001

Age at alloSCT2 (by 5 years)

1.02 (1–1.05)

0.11

1.05 (1.02–1.08)

0.002

1 (0.96–1.03)

0.86

1.1 (1.04–1.16)

<0.001

Disease status at alloSCT2

CR

1

 

1

 

1

 

1

 

Rel

1.63 (1.39–1.91)

<0.001

1.59 (1.34–1.88)

<0.001

1.91 (1.56–2.34)

<0.001

1.35 (1.02–1.8)

0.04

Cyto-genetics

Good

1

 

1

 

1

 

1

 

Interm

1.04 (0.71–1.53)

0, 85

1.09 (0.72–1.67)

0,68

1.14 (0.7–1.86)

0, 59

0.85 (0.43–1.71)

0, 65

Poor

1.26 (0.84–1.89)

0, 26

1.4 (0.9–2.18)

0, 14

1.39 (0.84–2.31)

0, 20

1.06 (0.51–2.2)

0, 87

NA

1.12 (0.76–1.66)

0, 56

1.18 (0.77–1.81)

0, 45

1.13 (0.69–1.85)

0, 63

1.08 (0.54–2.17)

0, 82

Female donor to male recipient

No

1

 

1

 

1

 

1

 

Yes

1.06 (0.87–1.28)

0, 58

0.94 (0.76–1.16)

0, 55

0.99 (0.78–1.26)

0, 92

1.13 (0.79–1.6)

0, 51

CMV status donor

Negative

1

 

1

 

1

 

1

 

Positive

1.04 (0.89–1.2)

0, 64

1.09 (0.93–1.28)

0, 26

1.02 (0.84–1.23)

0, 87

1.05 (0.81–1.37)

0, 71

In vivo T-cell depletion

No

1

 

1

 

1

 

1

 

Yes

0.92 (0.78–1.1)

0.37

0.89 (0.74–1.07)

0.20

1.05 (0.84–1.3)

0.68

0.7 (0.51–0.95)

0.02

Myelo-ablative regimen

No

1

 

1

 

1

 

1

 

Yes

0.79 (0.68–0.92)

0.002

0.82 (0.7–0.97)

0.02

0.7 (0.58–0.85)

<0.001

1.1 (0.84–1.44)

0.47

TBI

No

1

 

1

 

1

 

1

 

Yes

0.99 (0.83–1.18)

0, 89

1.05 (0.87–1.26)

0, 64

1 (0.79–1.26)

0, 99

0.95 (0.7–1.3)

0, 76

Karnofsky Index

< 90

1

 

1

 

1

 

1

 

≥ 90

0.84 (0.72–0.97)

0.02

0.74 (0.63–0.87)

<0.001

0.95 (0.78–1.15)

0.58

0.65 (0.49–0.85)

0.002

Interval alloSCT1 to 1st relapse

≥10.2mo

1

 

1

 

1

 

1

 

<10.2mo

1.72 (1.48–2)

<0.001

1.83 (1.56–2.15)

<0.001

1.86 (1.54–2.24)

<0.001

1.46 (1.11–1.93)

0.01

Interval relapse to alloSCT2 in mo

1.01 (0.98–1.03)

0, 70

1 (0.97–1.03)

0, 96

1.01 (0.98–1.04)

0,54

0.99 (0.95–1.04)

0,76

  1. LFS leukemia free survival, OS overall survival, RI relapse incidence, NRM non-relapse mortality, HR hazard ratio, CI confidence interval, alloSCT allogeneic stem cell transplantation, alloSCT1 first SCT, alloSCT2 second SCT, CR complete remission, Rel relapse, mo months, CMV cytomegalo virus, TBI total body irradiation, MSD matched sibling donor, Haplo haploidentical, URD unrelated donor, interm intermediate, NA not available.
  2. Significant values are in bold.
Back to article page